Unlocking Project Success in Pharma with Earned Value Management Best Practices
- Jordan Webb
- Jan 12
- 5 min read
Updated: Mar 5
Project success in the pharmaceutical and biotech industries depends on precise control of scope, schedule, and cost. Earned Value Management (EVM) offers a proven way to track these elements together, providing clear insights into project health. This post explains how EVM works, why it matters in pharma, and how to apply best practices aligned with PMI standards to improve project outcomes.
What Is Earned Value Management and Why It Matters in Pharma
Earned Value Management is a project management technique that integrates three key components:
Scope — the work that must be completed
Schedule — the timeline for completing the work
Cost — the budget allocated for the work
EVM measures project performance by comparing planned work and budget to actual progress and spending, helping to identify deviations early and allowing corrective actions before problems escalate.
In pharmaceutical projects, where timelines are tight and budgets often large, EVM supports controlling costs in research and manufacturing, managing complex supply chains for drug development, and tracking clinical trial phases and regulatory milestones. Using EVM reduces the risks of delays and cost overruns, which can have significant financial and compliance consequences in an industry where a single late-stage failure can represent billions of dollars in sunk investment. Clinical trials in later stages of pharmaceutical product development are particularly money and time consuming, and the estimates of total cost and timeline are often planned over-optimistically — EVM supports project managers by providing performance-based, regularly updated forecasts on total final cost and timeframe, which also serve as inputs to risk management and stakeholder communication (link).
Core EVM Metrics to Monitor
Understanding key EVM metrics is essential for effective project control. The three foundational data points are:
Planned Value (PV) — the budgeted cost for work scheduled to be done by a certain date
Earned Value (EV) — the budgeted cost for work actually completed by that date
Actual Cost (AC) — the real cost incurred for the work done.
From these three inputs, four critical performance indicators are derived:
Schedule Variance (SV) = EV - PV — indicates if the project is ahead or behind schedule
Cost Variance (CV) = EV - AC — shows if the project is under or over budget
Schedule Performance Index (SPI) = EV / PV — measures schedule efficiency
Cost Performance Index (CPI) = EV / AC — measures cost efficiency
An SPI below 1 means the project is behind schedule, while a CPI below 1 signals cost overruns. The fundamental premise for CPI and SPI is to incrementally check the progress of a project at set intervals to see if the project is tracking to its baseline — and in clinical studies, where monetary value can range from approximately $5M in a Phase I trial to exceeding $100M for a Phase III trial, crisp execution using these KPIs as benchmarks offers the opportunity to realize substantial financial savings (link). Monitoring these values regularly helps pharma project managers adjust resources or timelines proactively rather than reactively.
Applying EVM Best Practices in Pharmaceutical Projects
Pharma projects have unique challenges such as regulatory requirements, complex stakeholder involvement, and high uncertainty. Several best practices make EVM effective in this context.
Define a Clear Work Breakdown Structure (WBS). Breaking down the project into manageable, measurable components — for example, separating manufacturing scale-ups, regulatory submissions, and clinical trial phases into distinct WBS elements — improves scope control and makes earned value calculations more accurate. Without a well-defined WBS, the "E" in EVM loses its meaning, as there is no clear unit of work against which to measure progress.
Integrate EVM with Regulatory Milestones. Aligning EVM tracking with key regulatory deadlines such as Investigational New Drug (IND) submissions or New Drug Application (NDA) approvals ensures that schedule performance reflects critical compliance checkpoints, not just internal project timelines. In pharma, missing a regulatory milestone carries consequences far beyond a simple schedule slip.
Use Realistic Baselines. Setting baselines based on historical data and expert input is essential — overly optimistic schedules or budgets produce misleading EVM results that undermine the entire framework. Using past clinical trial data to estimate realistic timelines and costs, rather than aspirational projections, ensures that variances detected by EVM are meaningful signals rather than artifacts of poor planning.
Regularly Update and Communicate EVM Data. Updating EVM metrics frequently — ideally monthly or biweekly — captures project changes in near real time. Sharing reports with stakeholders in clear formats, highlighting variances and corrective actions, builds trust and supports faster decision-making across the cross-functional teams that characterize pharma drug development. Applying EVM principles not only supports informed decision-making but also enhances transparency and accountability among team members and stakeholders involved in the clinical trial. (link)
Incorporate Risk Management. Combining EVM with risk registers provides a fuller picture of project health — understanding not just current variances but what risks are likely to drive future ones. If a supply chain disruption is likely, adjusting the baseline and monitoring its effect on earned value metrics ensures the EVM framework remains credible and actionable rather than stale.
Train Teams on EVM Concepts. Ensuring project teams understand EVM principles and how their work affects the metrics encourages accurate progress reporting and fosters ownership of project performance. EVM is only as reliable as the data that feeds it, and that data comes from the people executing the work.
Example: Using EVM to Manage a Clinical Trial
Consider a Phase III clinical trial with a $10 million budget and an 18-month timeline. The project manager sets a baseline with planned values for patient recruitment, data collection, and analysis milestones.
At month 9, the EVM report shows:
Planned Value (PV) of $5 million
Earned Value (EV) of $4 million
Actual Cost (AC) of $4.5 million
The resulting calculations tell a clear story:
Schedule Variance (SV) = $4M - $5M = -$1M (behind schedule)
Cost Variance (CV) = $4M - $4.5M = -$0.5M (over budget)
Schedule Performance Index (SPI) = 0.8, meaning the project is completing only 80 cents' worth of work for every dollar of work planned (i.e., the project is 20% behind schedule).
Cost Performance Index (CPI) = 0.89, meaning only 89 cents of value is being earned for every dollar spent (i.e., the project is 11% over budget).
This data signals that the trial is delayed and costing more than planned. The project manager investigates the causes — such as slower-than-expected patient enrollment — and reallocates resources to recruitment efforts. This proactive response, made possible by the early visibility EVM provides, helps bring the trial back on track before the variance compounds into a more serious deviation.
Tools and Software for EVM in Pharma
Several project management tools support EVM calculations and reporting in pharmaceutical settings. Commonly used platforms include:
Microsoft Project with EVM plugins
Primavera P6
Deltek Cobra
Specialized pharma project management platforms
Choosing software that integrates with clinical trial management systems or regulatory tracking tools can improve data accuracy and reduce manual effort. Digital tools and automation are increasingly essential in clinical trial EVM, and best practices for their implementation include ensuring all solutions comply with data integrity standards, promoting collaboration across clinical operations, finance, and regulatory affairs, providing continuous staff training, and establishing regular review cycles to ensure ongoing compliance with evolving regulations. (link)
Conclusion / Call to Action
In the biotech and pharmaceutical industry, particularly in critical R&D projects, EVM offers exceptional insight into cost overruns and potential delays, enabling decisive action to ensure projects remain aligned with both business and regulatory objectives. When implemented with the right baseline discipline, regulatory alignment, and team engagement, EVM transforms project performance data from a rearview mirror into a forward-looking navigation tool. At Ganvion Biotech Solutions, we help clients implement and optimize EVM frameworks tailored to the complexity of biotech and pharma drug development — so that performance issues are surfaced early, corrective actions are taken proactively, and investments are protected throughout the project lifecycle.
